NVO Articles, Novo Nordisk A/S - From 05/02/24

Novo Nordisk A/S (NYSE:NVO) is witnessing a surge in the number of patients starting on its weight-loss drug, Wegovy, in the U.S. This increase com...

The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate...

Denmark’s healthcare authority has decided to favor less expensive drugs for type 2 diabetes patients, impacting the prescription of costlier...

The Senate Committee on Health, Education, Labor, and Pensions is reportedly scrutinizing  Novo Nordisk A/S (NYSE:NVO) ‘s pric...

A recent survey conducted by Morgan Stanley reveals that the use of GLP-1 drugs, popular for weight loss and diabetes, is affecting consu...

Thursday, Germany’s competition authority, Bundeskartellamt, cleared the planned acquisition of Cardior Pharmaceuticals GmbH&n...

The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says t...

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 27.13% on an annualized basis producing an average annual return of 39...

U.S. District Judge Roy Altman ruled that the drugmaker Eli Lilly And Co (NYSE:LLY) cannot rely on state law to stop a compound...

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evid...